AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer
AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acquisition.